Evidence map›Paper›PMID 42614774›Full record

ArticleAnnals of clinical epidemiology2026

Cefazolin Dose-Response-based Correlation of Weight With Orthopaedic Implant-related Surgical-site Infections.

Masaki Hatano, Yusuke Sasabuchi, Koji Yamada, Shotaro Aso, Hisatoshi Ishikura, Takeyuki Tanaka, Sakae Tanaka, Hideo Yasunaga

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Masaki HatanoDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Yusuke SasabuchiDepartment of Real-world Evidence, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Koji YamadaDepartment of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Shotaro AsoDepartment of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hisatoshi IshikuraDepartment of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Takeyuki TanakaDepartment of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Sakae TanakaDepartment of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Hideo YasunagaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the association of the initial body weight-stratified cefazolin antimicrobial prophylaxis (AMP) dose and surgical-site infection (SSI) in major orthopedic implant surgery.

methodsThis nationwide, retrospective cohort study used data from the Diagnosis Procedure Combination database. We included patients (age ≥18 years) who underwent major orthopedic implant surgery between July 2010 and March 2022. Patients underwent surgery with an initial cefazolin dose of either 1 g (1 g cefazolin group) or 2 g (2 g cefazolin group). Primary outcome was in-hospital SSI. Restricted cubic spline functions were used to estimate the nonlinear association of body weight-stratified cefazolin dose with the outcome and between cefazolin dose per weight and the outcome.

resultsAmong the 408,487 participants, 394,731 and 13,756 were in the 1 g and 2g cefazolin groups, respectively. The 1 g cefazolin group, but not the 2 g cefazolin group, showed a J-shaped relationship between body weight and SSI, which increased continuously beyond 50 kg, in an increased risk of SSI with body weight. A reverse J-shaped relationship was observed between cefazolin dose per weight and SSI, with an increased risk of SSI at <20 mg/kg.

conclusionAn increased risk of SSI was observed with 1 g cefazolin, but not with 2 g cefazolin, as an initial AMP with higher body weight among adults weighing >50 kg.

Indexed as

antimicrobial prophylaxiscefazolindoseorthopaedic surgerysurgical site infection

Identifiers

PMID42614774
PMCPMC13482528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.